Drugs / BGT007
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06645301 | Nov 2024 → Aug 2026 overdue | colorectal cancer, malignant pancreatic neoplasm | BioSyngen Pte Ltd | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06104241 | Oct 2023 → Oct 2026 expected | digestive system cancer | The Affiliated Hospital of Xuzhou Medical University | Recruiting | No outcome recorded |
| Phase 0 | NCT05616468 | Dec 2022 → Dec 2024 | nasopharyngeal carcinoma | The Affiliated Hospital of Xuzhou Medical University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BGT007 | “BGT007 3.0×10\^8cells,Intravenous infusion，3 subject is planned to be enrolled” NCT06645301 ↗ |
| Modality | Cell therapy | “BGT007 cells (d0) were infused intravenously once” NCT05616468 ↗ |
| Route | Intravenous | “BGT007 cells (d0) were infused intravenously once” NCT05616468 ↗ |